20 YEARS OF PROFESSIONAL & DEDICATED SERVICE TO GLOBAL CUSTOMERS

Custom Manufacturing, Project Outsourcing, your Trusted Partner from China

Real-World Data on Lorlatinib: Efficacy Beyond Clinical Trials

Clinical trials are the cornerstone of drug development, providing rigorous evidence for a treatment's efficacy and safety. However, real-world data (RWD) offers invaluable insights into how a medication performs in everyday clinical practice, across a broader spectrum of patients and healthcare settings. For lorlatinib, a powerful third-generation ALK inhibitor for ALK-positive non-small cell lung cancer (NSCLC), RWD is increasingly confirming the promising results seen in clinical trials.

Studies analyzing real-world patient populations have consistently shown lorlatinib to be effective in controlling disease progression, including in patients who have developed resistance to earlier ALK inhibitors. These real-world observations often mirror the findings from pivotal trials, demonstrating significant progression-free survival (PFS) benefits. Particularly noteworthy is lorlatinib's continued efficacy in patients with brain metastases, a challenging aspect of the disease that earlier therapies struggled to address effectively.

Furthermore, RWD provides critical information on the tolerability and safety profile of lorlatinib in broader patient groups. While side effects are present, as with any potent medication, real-world experiences often highlight the manageability of these effects through appropriate clinical intervention and patient monitoring. The data also sheds light on the practical aspects of lorlatinib use, such as its oral administration and its role in sequencing treatment regimens.

The availability of high-quality pharmaceutical ingredients is essential for generating reliable real-world data. Suppliers like NINGBO INNO PHARMCHEM CO.,LTD. contribute to this by ensuring the consistent purity and availability of lorlatinib, allowing healthcare systems worldwide to gather and analyze crucial information. The buy price of lorlatinib also plays a role in its accessibility for research and clinical use, facilitating a deeper understanding of its long-term benefits and optimal application in patient care.

Manufacturing Facilities

NINGBO INNO PHARMCHEM CO.,LTD. was established in 2007. It is committed to the R&D, production and sales of raw materials, pharmaceutical intermediates and fine chemicals. We striving to create a high-efficiency and high-quality integrated chemical service platform to better serve domestic and foreign customers.

Professional Export Experience

to Global Customers

WHY CHOSE US?

1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;

2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;

3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).

FAQ

  • A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.

  • A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.

  • A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.

CONTACT US
Should you need to contact us; you may call during regular business hours, Monday through Friday, 8am – 6 pm.
NINGBO INNO PHARMCHEM CO.,LTD.
Address: No.163 Ruiqing Rd.,Ningbo 315000 China
Phone: 86-574-87319282
Fax: 86-574-27912196
SEND US AN EMAIL

NAME*

EMAIL*

COMPANY

COUNTRY*

MESSAGE*

Previous: Navigating Treatment: Side Effects and Management of Lorlatinib

Next: The Future of Lung Cancer Treatment: Advances in Targeted Therapies

All Rights Reserved